Lawsuit Alleges Xarelto Manufacturers Failed to Communicate Risks of DrugA new Xarelto lawsuit filed alleges that the manufacturers of Xarelto failed to adequately warn patients and doctors about the real dangers of the drug. BloodThinnerHelp.com reports today on one of the more notable lawsuits filed in the Xarelto multidistrict litigation. The lawsuit originated in federal court for the Eastern District of New York and was filed by a woman in Texas. The lawsuit alleges that the manufacturers of Xarelto failed to adequately warn doctors and patients about the dangers of Xarelto and that the manufacturers failed to perform sufficient safety testing on the blood thinner. The lawsuit finally alleges that these failures by Xarelto’s manufacturers led to the plaintiff’s serious injuries.
This lawsuit has since been consolidated into the federal multidistrict litigation against the manufacturers of Xarelto headquartered out of the United States District Court for the Eastern District of Louisiana. The case is filed under federal court docket number 1:14-CV-04524. The full complaint can be downloaded and read here.
The plaintiff in this particular lawsuit was initially prescribed Xarelto by her primary care doctor to prevent blood clots that developed as a result of atrial fibrillation, a heart condition she suffered from. The plaintiff was taking the blood thinner as directed for five months when she suffered from a life threatening internal bleeding event that left her with serious injuries. The complaint does not specify the exact nature of the plaintiff’s injuries in this case but it does detail that the injuries she suffered from are permanent and will require future long term care as a direct result of the uncontrollable internal bleeding.
Lawsuits Allege Xarelto Has Dangerous Defect
Xarelto was initially approved by the Food and Drug Administration, FDA, in 2011 to treat atrial fibrillation, deep vein thrombosis, and to be used in patients who have recently undergone a hip or knee replacement surgery. Xarelto was marketed as a more convenient alternative to the traditional blood thinner Warfarin because Xarelto does not require the restrictive diet and constant blood monitoring that Warfarin does. Since then, the FDA has released several warnings about the dangers of Xarelto and even attached two black box warnings to the drug. The black box warning is the most strict warning the FDA can attach to a drug short of recalling it. The complete list of FDA warnings regarding Xarelto can be found here.
Xarelto works differently than other blood thinners because it is part of a new class of blood thinners called Xa inhibitors. Xa inhibitors prevent blood clots by blocking the agent in the blood that is responsible for making the blood clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood’s ability to clot. This is dangerous because Xarelto does not come with a corresponding antidote to reverse its anticoagulant effects, meaning that if a patient suffers from an internal bleeding injury while taking Xarelto, there is no way to stop their bleeding and the situation can turn into a dangerous uncontrollable bleeding event very quickly.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.